A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

Arms (1)

1. type

   EXPERIMENTAL

   label

   single arm

   interventionNames

   1. Biological: monoclonal antibody
   2. Drug: chemotherapy

Primary outcomes (1)

1. measure

   Number of Participants With Dose Limiting Toxicities (DLTs)

   timeFrame

   Baseline up to Cycle 1 / Day 28

   description

   Any of the following during first cycle of treatment and attributable to CP-870893: afebrile Grade (Gr) 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) ≥7 days or Gr 3 or 4 neutropenia associated with fever (1 oral temperature \>38.5 degrees Celsius (C) or 3 oral temperatures \>38.0 degrees C in a 24-hour period); Gr 4 thrombocytopenia or Gr 3 thrombocytopenia associated with bleeding; Gr 4 lymphopenia, if coupled with clinical consequence (such as, opportunistic infection) or any other Gr 3 hematological adverse events; ≥Gr 3 non-hematologic toxicities (except alopecia).